00000nam 2200000zi 4500 9.914493 CaOODSP 20230120085522 m o d f cr cn||||||||| 220816e20220819onc ob f000 0 eng d 9780660450681 (report) 9780660450698 (summary) CaOODSP eng rda CaOODSP n-cn--- HP5-141/1-2022E-PDF HP5-141/2-2022E-PDF Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age. Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, August 19, 2022. ©2022 1 online resource (17 pages) + 1 summary (5 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Recommandations sur l'utilisation d'une première dose de rappel du vaccin Comirnaty de Pfizer-BioNTech contre la COVID-19 chez les les enfants de 5 à 11 ans. At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Includes bibliographical references (pages 14-17). COVID-19 vaccines Canada. COVID-19 (Disease) Vaccination Canada. Vaccination of children Canada. COVID-19 vaccines Government policy Canada. COVID-19 (Disease) Vaccination Government policy Canada. Vaccination of children Government policy Canada. Public Health Agency of Canada, issuing body. Recommandations sur l'utilisation d'une première dose de rappel du vaccin Comirnaty de Pfizer-BioNTech contre la COVID-19 chez les les enfants de 5 à 11 ans. (CaOODSP)9.914494 Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration. (CaOODSP)9.917987 PDF 928 KB https://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-141-1-2022-eng.pdf (report) PDF 954 KB https://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-141-2-2022-eng.pdf (summary) 220374 (report) 220376 (summary)